Alentis and PinotBio Formed Biotech Partnership
The two companies entered a licensing agreement to develop new antibody-drug conjugates for cancer treatment.
Updated on Oct. 14, 2026 in Biotech
Live Poll
Do you believe pharmaceutical research partnerships effectively accelerate the development of new cancer treatments?
Alentis Therapeutics and PinotBio have announced a research collaboration to develop antibody-drug conjugates (ADCs). The agreement focuses on targeting claudin-1 to address unmet needs in oncology.
Why it matters
This collaboration seeks to improve cancer treatment outcomes by leveraging specific antibody portfolios and novel platform technologies to overcome resistance mechanisms.
The partnership integrates the Alentis antibody portfolio with PinotBio's PINOT-ADC platform, which utilizes specialized linkers and payloads. These components are designed to target claudin-1, a protein found in more than ten distinct tumor types.
The players
Alentis Therapeutics
Headquartered in Basel, Switzerland, this clinical-stage biotech firm focuses on developing therapies for organ fibrosis and cancer.
PinotBio
Based in Suwon, South Korea, this company specializes in developing proprietary antibody-drug conjugate platforms for targeted cancer treatments.
The details
Alentis Therapeutics secured an exclusive option to in-license PinotBio's proprietary linker and payload technology. The contract structure includes an upfront payment, various development and commercial milestones, and ongoing royalties on future net sales.
Timeline
October 14, 2026: Alentis and PinotBio officially announced their new collaboration agreement.
The Tech Race
This collaboration marks an expansion of the PINOT-ADC platform into broader oncology applications, following its established use in targeted drug delivery. By combining novel linkers and payloads with specific antibody targeting, the companies are competing to overcome long-standing drug resistance issues in cancer therapy.
While this agreement focuses on early-stage research, its success could eventually lead to new, more effective treatment options for patients with various cancer types. The development of these therapies may influence future clinical trial availability and long-term cancer care standards.
The takeaway
This partnership highlights the industry trend of combining specialized antibody targeting with sophisticated payload technology to fight complex tumors. Such collaborations are essential for companies aiming to bridge the gap between initial research and viable commercial oncology treatments.
Further reading
Learn more about the latest industry developments in the Biotech section.
Live Poll
Do you believe pharmaceutical research partnerships effectively accelerate the development of new cancer treatments?
